ArticleOncotarget2015
Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 89 citations in OpenAlex.
- Prostate Cancer-Associated Fibroblasts: A Review on CAF Functions, Heterogeneity, Resistance Mechanisms, and Future in a Chip.International journal of molecular sciences · 2026Review
- Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis.Molecular oncology · 2025Article
- Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis.Science advances · 2025Article
- Review
- AR loss in prostate cancer stroma mediated by NF-κB and p38-MAPK signaling disrupts stromal morphogen production.Oncogene · 2024Article
- Distinct mesenchymal cell states mediate prostate cancer progression.Nature communications · 2024Article
- Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor.Frontiers in immunology · 2024Review
- Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.The journal of pathology. Clinical research · 2023Article
- Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer.Endocrinology · 2023Review
- Early Cell Cultures from Prostate Cancer Tissue Express Tissue Specific Epithelial and Cancer Markers.International journal of molecular sciences · 2023Article
- Inflammatory response to Trichomonas vaginalis in the pathogenesis of prostatitis and benign prostatic hyperplasia.Parasites, hosts and diseases · 2023Review
- Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer.Biomolecules · 2022Review
- Activin B and Activin C Have Opposing Effects on Prostate Cancer Progression and Cell Growth.Cancers · 2022Article
- Review
- Stromal AR inhibits prostate tumor progression by restraining secretory luminal epithelial cells.Cell reports · 2022Article
- Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.Endocrine oncology (Bristol, England) · 2022Review
- Roles of steroid receptors in the lung and COVID-19.Essays in biochemistry · 2021Review
- The androgen receptor/filamin A complex as a target in prostate cancer microenvironment.Cell death & disease · 2021Article
- The Role of Androgen Receptor in Cross Talk Between Stromal Cells and Prostate Cancer Epithelial Cells.Frontiers in cell and developmental biology · 2021Review
- Article
Corrections and comments
- Erratum issuedErratum: Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.2015 · Palenthorpe, Helen M [Corrected to Palethorpe, Helen M]
Authors and funding
19 authors at 9 institutions in 2 countries.
Funding
Abstract
Androgen receptor (AR) signaling in stromal cells is important in prostate cancer, yet the mechanisms underpinning stromal AR contribution to disease development and progression remain unclear. Using patient-matched benign and malignant prostate samples, we show a significant association between low AR levels in cancer associated stroma and increased prostate cancer-related death at one, three and five years post-diganosis, and in tissue recombination models with primary prostate cancer cells that low stromal AR decreases castration-induced apoptosis. AR-regulation was found to be different in primary human fibroblasts isolated from adjacent to cancerous and non-cancerous prostate epithelia, and to represent altered activation of myofibroblast pathways involved in cell cycle, adhesion, migration, and the extracellular matrix (ECM). Without AR signaling, the fibroblast-derived ECM loses the capacity to promote attachment of both myofibroblasts and cancer cells, is less able to prevent cell-matrix disruption, and is less likely to impede cancer cell invasion. AR signaling in prostate cancer stroma appears therefore to alter patient outcome by maintaining an ECM microenvironment inhibitory to cancer cell invasion. This paper provides comprehensive insight into AR signaling in the non-epithelial prostate microenvironment, and a resource from which the prognostic and therapeutic implications of stromal AR levels can be further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.